Hrs-3095

Phase 1

AAtridia Pty Ltd.

Hrs-3095 is one of 10 therapeutic programs targeting Chronic Spontaneous Urticaria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Spontaneous UrticariaActive, not recruiting

Chronic Spontaneous UrticariaPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Chronic Spontaneous Urticaria

#DrugCompanyPhaseTrials

Claritin

PPerrigo Company

Approved

1 2

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

1 3

Barzolvolimab

CCelldex Therapeutics

Phase 3

4 4

JYB1904

JJemincare

Phase 3

2 5

LOU064

Novartis

Phase 3

3 6

CM512

KKeymed Biosciences Co.Ltd

Phase 2

1 7

Human Interleukin-2 (IL-2) (proleukin)

NNova Scotia Health Authority

Phase 3

1 8

BGB-16673

BBeOne Medicines

Phase 1

1 9

Hrs-3095

AAtridia Pty Ltd.

Phase 1

1 10

BBT001

BBambusa Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria1 trial

A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants

Active, not recruiting·AAtridia Pty Ltd.·Phase 1·NCT07686484·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hrs-3095. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hrs-3095. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Atridia Pty Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAtridia Pty Ltd.

Hrs-3095

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Chronic Spontaneous Urticaria1 trial

References

Drug Info

Quick Facts

Related News